Literature DB >> 10229502

Atypical teratoid/rhabdoid tumor of the CNS: cytopathology and immunohistochemistry of insulin-like growth factor-II, insulin-like growth factor receptor type 1, cathepsin D, and Ki-67.

S Ogino1, M L Cohen, F W Abdul-Karim.   

Abstract

Insulin-like growth factor (IGF)-II is a potent growth factor, normally controlled by a number of other factors, including IGF binding proteins and IGF binding protein proteases. In general, the latter increase the bioavailability of IGF by cleaving IGF binding proteins. Cathepsin D (an IGF binding protein protease) was also implicated in tumor invasion. Although IGF-II was implicated in the pathogeneses of various childhood neoplasms, its significance in the pathogenesis of atypical teratoid/rhabdoid tumor of the central nervous system (ATRT-CNS) was not studied to date. We present clinicopathologic features of two cases of ATRT-CNS. In addition, formalin-fixed, paraffin-embedded tissue sections were stained immunohistochemically for IGF-II, IGF receptor type 1, cathepsin D, and Ki-67. Both tumors demonstrated diffuse strong cytoplasmic positivity for IGF-II, diffuse cytoplasmic and focal membranous positivity for IGF receptor type I, and diffuse cytoplasmic positivity for cathepsin D. The Ki-67 labeling indices were 10.0% and 1.4%. We conclude that ATRT-CNS cells express both IGF-II and IGF receptor type 1, supporting the hypothesis that autocrine/paracrine stimulation of cell growth by IGF-II might be one mechanism involved in ATRT-CNS tumorigenesis. Cathepsin D expressed by the tumor cells might also be involved in both tumor cell invasion and growth. The exact pathogenesis of ATRT-CNS remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10229502

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  6 in total

1.  Epigenetic modification after inhibition of IGF-1R signaling in human central nervous system atypical teratoid rhabdoid tumor (AT/RT).

Authors:  Kyu-Won Shim; Guifa Xi; Barbara-Mania Farnell; Dong-Seok Kim; Takao Tsurubuchi; Tadanori Tomita; C Shekhar Mayanil
Journal:  Childs Nerv Syst       Date:  2013-04-28       Impact factor: 1.475

2.  Atypical teratoid/rhabdoid tumor with hereditary multiple exostoses in an 18-year-old male: A case report.

Authors:  Qian Wu; B O Xiao; L I Li; L I Feng
Journal:  Oncol Lett       Date:  2015-06-17       Impact factor: 2.967

Review 3.  Atypical teratoid/rhabdoid tumor: the controversy behind radiation therapy.

Authors:  Sarah E Squire; Michael D Chan; Karen J Marcus
Journal:  J Neurooncol       Date:  2006-07-20       Impact factor: 4.130

4.  Profiling pathway-specific novel therapeutics in preclinical assessment for central nervous system atypical teratoid rhabdoid tumors (CNS ATRT): favorable activity of targeting EGFR- ErbB2 signaling with lapatinib.

Authors:  Anjali Singh; Xueqing Lun; Aarthi Jayanthan; Halah Obaid; Yibing Ruan; Douglas Strother; Susan N Chi; Amy Smith; Peter Forsyth; Aru Narendran
Journal:  Mol Oncol       Date:  2013-01-11       Impact factor: 6.603

5.  Novel role for insulin as an autocrine growth factor for malignant brain tumour cells.

Authors:  Alexandre Arcaro; Kathrin T Doepfner; Danielle Boller; Ana S Guerreiro; Tarek Shalaby; Shaun P Jackson; Simone M Schoenwaelder; Olivier Delattre; Michael A Grotzer; Barbara Fischer
Journal:  Biochem J       Date:  2007-08-15       Impact factor: 3.857

6.  High-dose chemotherapy and autologous stem cell rescue for atypical teratoid/rhabdoid tumor of the central nervous system.

Authors:  Theodore Nicolaides; Tarik Tihan; Biljana Horn; Jaclyn Biegel; Michael Prados; Anuradha Banerjee
Journal:  J Neurooncol       Date:  2009-11-22       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.